GOLDILOX

A Phase IIB, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction, Persistent Inflammation, and Elevated N-terminal Prohormone Brain Natriuretic Peptide

Stadium
klaar
Middel
MEDI6570
Populatie
ASCVD
Fase
IIB
First Patient In
19 januari 2022
Last Patient In
23 december 2022
Last Patient Last Visit
11 november 2023

National Lead

dr. mr. A.J.M. Oude Ophuis

Cardioloog

Contact Kantoor

S. Jansen

Studiemanager

De pagina is verlopen.